Ireland
--:--IST
Recruiting Not applicable

Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation

NCT06853886 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-08-12
Last updated
2026-05-20

Condition(s) studied

Chronic Hepatitis B Virus

Investigational drug(s) / intervention(s)

blood sample HBV patientblood sample healthy volunteers

blood sample HBV patient: During a boold sample at only one follow up visit: * 3 tubes EDTA 10 ml per patient * 1 tube "Paxgene" 1ml * 2 dry tube per patient

blood sample healthy volunteers: * 3 tubes EDTA ideally age and sex matched to CHB patient. * 1 tube "Paxgene" 1ml * 2 dry tube

Study summary

Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Male or female, age ≥18 years old * HBV infection or chronic HBV infection untreated or treated with a nucleoside or nucleotide analog * Willing and able to provide written informed consent * Affiliated with a social securityregimen Healthy volunteer must meet all of the following inclusion criteria to be eligible for participation in this study: * Male or female, age between 18 and 80 years * Willing and able to provide written informed consent Exclusion Criteria: * Co-infection with HCV, HIV or HDV (or HBV for healthy volunteer) * Acute hepatitis in the year preceding recruitment * Other liver diseases : alcohol, obesity (BMI\>30), diabetes, metabolic syndrome (dyslipidemia and/or known hypertension) - Underlying immunological or cancerous diseases * Patient with a disability that prevents him/her from fully understanding the requirements of the trial - Patient under court protection, guardianship or curatorship * Pregnant or breast-feeding women. Secondary exclusion criteria: * A healthy volunteer whose vaccination status does not match that expected on the basis of serological results * Positive blood pregnancy test on inclusion * Positive HCV, HIV or HDV test in a patient * Positive HBV, HCV, HIV or HDV test in a healthy volunteer

Primary outcome measure(s)

  • RNA sequencing of B cells from CHB patients at different stages, description of their molecular signature — At inclusion, day 0

Trial sites (3)

FacilityCityRegionStatus
Centre d'Investigation Clinique Limoges France Recruiting
Limoges University Hospital Limoges France Recruiting
Hospice civils de Lyon Lyon France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06853886 on ClinicalTrials.gov ↗ ← All trials in France